Free Trial

Zymeworks (NASDAQ:ZYME) Shares Gap Up on Analyst Upgrade

Zymeworks logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zymeworks shares rose premarket after Citizens JMP raised its price target from $32 to $39, maintaining an “outperform” rating; shares opened at $27.47 versus a prior close of $26.24.
  • Analyst sentiment is broadly positive: 12 analysts rate the stock Buy, one Hold and one Sell, giving it a “Moderate Buy” consensus and an average price target of $43.25.
  • The company reported quarterly revenue of $512.92 million, up 828.7% year over year and above analysts’ $227.40 million estimate; EPS of $2.28 also narrowly beat consensus.
  • Five stocks to consider instead of Zymeworks.

Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) shares gapped up before the market opened on Monday after Citizens Jmp raised their price target on the stock from $32.00 to $39.00. The stock had previously closed at $26.24, but opened at $27.47. Citizens Jmp currently has a market outperform rating on the stock. Zymeworks shares last traded at $27.2150, with a volume of 88,663 shares traded.

Several other analysts also recently weighed in on ZYME. Truist Financial boosted their price objective on Zymeworks from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Tuesday, November 10th. Citigroup raised their target price on shares of Zymeworks from $39.00 to $44.00 and gave the stock a "buy" rating in a report on Wednesday, November 11th. Wolfe Research began coverage on shares of Zymeworks in a research note on Thursday, September 17th. They issued an "outperform" rating on the stock. HC Wainwright upped their price target on shares of Zymeworks from $55.00 to $56.00 and gave the company a "buy" rating in a report on Tuesday, November 10th. Finally, JPMorgan Chase & Co. upped their price target on shares of Zymeworks from $31.00 to $33.00 and gave the company an "overweight" rating in a report on Thursday, September 3rd. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $43.25.

View Our Latest Analysis on ZYME

Insider Activity

In related news, insider Paul Moore sold 39,741 shares of the business's stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $26.07, for a total transaction of $1,036,047.87. Following the transaction, the insider owned 33,756 shares in the company, valued at $880,018.92. The trade was a 54.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Adam Schayowitz sold 13,832 shares of the stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.85, for a total transaction of $357,557.20. Following the completion of the transaction, the executive vice president directly owned 23,205 shares of the company's stock, valued at approximately $599,849.25. The trade was a 37.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Rubric Capital Management LP raised its holdings in Zymeworks by 21.7% in the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock worth $175,280,000 after purchasing an additional 1,250,000 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Zymeworks during the 2nd quarter valued at $111,122,000. Perceptive Advisors LLC boosted its holdings in shares of Zymeworks by 7.6% during the 1st quarter. Perceptive Advisors LLC now owns 3,510,078 shares of the company's stock valued at $87,892,000 after buying an additional 248,228 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Zymeworks by 20.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,508,069 shares of the company's stock worth $39,949,000 after buying an additional 256,042 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Zymeworks by 6.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 743,898 shares of the company's stock worth $18,627,000 after buying an additional 43,896 shares during the period. Institutional investors own 92.89% of the company's stock.

Zymeworks Stock Performance

The stock's 50-day moving average price is $27.32 and its two-hundred day moving average price is $25.48. The stock has a market capitalization of $1.86 billion, a PE ratio of 51.81 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The company had revenue of $512.92 million during the quarter, compared to analysts' expectations of $227.40 million. During the same period last year, the company posted ($0.26) EPS. Zymeworks's revenue was up 828.7% on a year-over-year basis. On average, analysts predict that Zymeworks Inc. will post 1.31 earnings per share for the current fiscal year.

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company's lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zymeworks Right Now?

Before you consider Zymeworks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.

While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines